Member Info for uxm484

It's the potential size of placing required looking at all costs. It will likely be very big. Financials to me don't seem well managed. Just being honest.

I'm sorry I was thinking of investing but no chance now. The placing is likely to be very big so no thank you. This should be valued at 25-30 p I think. I agree cash now much be less than 10 million but look at total expenses. It's not good.

Cash and cash equivalents of £15.5 million as of 31 December 2021 (2020: £8.8 million)

· Net assets of £23.2 million as of 31 December 2021 (2020: £28.0 million)

· Loss and total comprehensive income for the full year 2021 was £54.7 million (2020: £25.9 Million)

· Research and Development Expenses was £19.8 million (2020: 22.0 million); General and Administrative Expense was £7.3 million (2020: £6.0 million)

· Listed on the NASDAQ Global Market under ticker symbol 'LBPS' after completing the merger with Longevity Acquisition Corporation, a special purpose acquisition company (SPAC) on 22 March 2021

· Along with the Longevity Acquisition Corporation merger we completed a concurrent private placement, raising total gross proceeds of approximately $39.8 million.

· Entered into a senior secured credit facility for up to $30 million with Oxford Finance LLC, including the initial drawdown of the first tranche for $12.5 million, with the remaining $7.5 million and $10 million tranches dependent on the achievement of certain milestones.

Loss of 54 million. Research development cost 19.8 million and expenses 7.3 million. Only 15 million cash. I don't like loan facilities. Financial position to me does not look very good at all. Surely a very placing will happen soon?

Cash and cash equivalents of £15.5 million as of 31 December 2021 (2020: £8.8 million)



· Net assets of £23.2 million as of 31 December 2021 (2020: £28.0 million)



· Loss and total comprehensive income for the full year 2021 was £54.7 million (2020: £25.9 Million)



· Research and Development Expenses was £19.8 million (2020: 22.0 million); General and Administrative Expense was £7.3 million (2020: £6.0 million)



· Listed on the NASDAQ Global Market under ticker symbol 'LBPS' after completing the merger with Longevity Acquisition Corporation, a special purpose acquisition company (SPAC) on 22 March 2021



· Along with the Longevity Acquisition Corporation merger we completed a concurrent private placement, raising total gross proceeds of approximately $39.8 million.



· Entered into a senior secured credit facility for up to $30 million with Oxford Finance LLC, including the initial drawdown of the first tranche for $12.5 million, with the remaining $7.5 million and $10 million tranches dependent on the achievement of certain milestones.

https://www.valirx.com/news/valirx-update-proposed-sub-license-val201

Oops could it be the return of the seller.

Very risky atm until TR1 is out. Think risk will be reduced in the 20s though.

The seller has not completely sold out. Very risky as can easily go back to the 20s with him sitting around and ready to sell.

I would wait until 25p before investing imo. Far to risky with a 50% downside here.

A free ride here at this price imo.

Still expect RNS next week. Only problem it will be hard for anyone to get in once it arrives.

Buy low and sell high and we are low almost as low as it can be.

Great logical posts earlier this morning. I agree no delay and news next week.

Looks like my 60p average will be reached next week. Very promising. Finally Val about to come good. 35p close today.

45p last time before news. 65p after news. Strong build up anticipated to news next week. This will rocket after deal.

Suzy expects no delays for 201. This should be a great build up to news.

It's not unusual to get a placing straight after the AGM.

That should really put the business in a solid position with some case. All for a placing after AGM and we can build from that level.

GL all genuine holders this will be a fantastic year.

Market cap was very high here so if trials failed always a huge risk. It was a great buy in price early today with cash balamce though.

My strategy is to buy undervalued stock with huge potential like Valirx the upside is far better and downside less risky.

Placing after placing here. This stock has been diluted so much that i do not see it going anywhere. Worth considering selling on this little spike as it will be likely not be long until the next placing arrives yet again.

PYC a dead stock that does f*** all. You been ramping this for years and still nothing. What a loser.

Desperation. Don't be surprised to see a huge placing at PYC in the coming months. No real cash being generated

Signs Service Agreement with TheoremRx



London, UK - ValiRx Plc (AIM: VAL), a life science company focusing on early-stage cancer therapeutics and women's health, announces today it has entered into a Service Agreement with TheoremRx Inc. ("TheoremRx"), a recently incorporated company, to enable ValiRx to work with TheoremRx to engage with Clinical Research Organisations (CROs) and supporting vendors for the next clinical trial of VAL201.

This Service Agreement was contemplated by the Letter of Intent announced by the Company on 2 November 2021, which outlined the intention of ValiRx and TheoremRx to enter into a sub-license to enable TheoremRx to develop VAL201 in the field of oncology. Completion of the sub-license is subject to the successful fundraise by TheoremRx.

TheoremRx is a private US-based oncology company focused on the discovery and development of new treatments that will benefit patients suffering from cancer. TheoremRx has established a highly integrated approach for the discovery, development and manufacture of peptide and small molecule drugs that modulate targets of clinical interest.

This Service Agreement enables ValiRx to work as a consultant to TheoremRx and will receive market rate, fair value consultancy fee, invoiced each calendar month until the termination of the Service Agreement, for the provision of consultancy services. The consultancy work contemplated by the Service Agreement includes introductions to CROs, requesting proposals, reviewing and advising on proposals and co-ordinating the scientific efforts to commence the next clinical trial of VAL201; enabling trial set up procedures to be executed in parallel to the fund-raising period. This signature confirms the commencement date of the Service Agreement to be 1 November 2021.

Further to the Company's announcement on 20 December 2021, the Company outlines the following steps of the documentation completed to-date towards the full execution of the sub-license of VAL201 for oncology to TheoremRx:

- Letter of Intent, announced on 2 November 2021, detailing the terms under which the sub-license will be signed;

- the amendment of the license between ValiRx and CRT, announced on 20 December 2021;

- the approval of the sub-license with TheoremRx by CRT, also announced on 20 December 2021; and

- the Service Agreement as detailed in this announcement.

The sub-license completion is subject to a successful fund-raise, with completion anticipated by end-Q1 2022.

The Letter of Intent and proposed sub-license therefore remain non-binding and there is no guarantee that this sub-license will be executed or that it will generate material revenues within the expected timeframe or at all.

Dr Suzy Dilly, CEO of ValiRx commented: "The work we have done with TheoremRx since signing the Letter of Intent in November 2021 has involved both the negotiation and finalisation of documents between TheoremRx, ValiRx and CRT, but has also started the pr

Very positive. I can see the SP doubling in the coming days given our current market cap.

VAL will be representing the growth companies from the pharma sector this Tuesday 7th December between 6pm-8pm. Register from the VAL LSE group if you wish to attend the presentation.

So what would you say should be the market cap of SAR and why? Let us see a logical answer rather than some robotic response pal.

Looks like a few want a cheaper entry.

Ignore the noise on here. Call it a bad deal if we were £1 plus at the moment but not at the current valuation. Do your own research guys.